death
cf
patientsj
occur
less
often
presum
therapi
antist
aphylccocc
antibiot
sever
properti
mediat
pathogenesi
aureu
cf
patient
cell
wall
of
aueu
import
allow
colon
cf
patient
avoid
pfiagocytosi
smwive
grow
high
naci
concentr
growth
nut
us
enhmlc
p
hydr
oxyphenylac
tic
acid
mad
oleic
acid
elev
cf
respiratori
secretiohsj
also
produc
exotoxin
alpha
delta
toxin
winch
caus
tissu
injuri
although
associ
well
character
aureu
colon
cf
patient
may
oredispos
coinfect
withpseudomona
aerunosa
indic
treat
aureu
clear
isol
sputum
may
due
either
colon
infect
furthermor
sputum
cultur
may
accur
recoveri
sputum
sampl
may
indic
upper
airway
colon
therefor
surpris
investig
treatment
show
vari
result
physician
propos
prophylact
use
antibiot
howev
one
doublebllnd
placebocontrol
studi
show
decreas
iaorbid
areu
mad
haemophilu
influenza
concomit
increas
mucoid
p
aeraginosa
colon
other
recommend
therapi
or
aureu
acut
pulmonm
exacerb
isol
sputum
sampl
current
doubleblind
placebocontrol
c
finic
trial
continu
cephalexin
therapymay
elucid
valu
earli
empir
antist
aphylococc
therapi
young
cif
role
ofh
influolba
cf
remain
unclear
addit
cf
nonencapsul
h
influenza
also
found
often
patient
chronic
pulmonari
diseas
bronchiti
bronchiectasi
howev
rayner
et
al
found
h
fluenza
isol
frequent
lower
respiratori
tract
cf
patient
asthmat
investig
also
found
increas
isol
ofh
influenza
preced
exacerb
colon
reduc
antibiot
therapi
isol
rate
vari
tend
relat
cultur
techniqu
previou
studi
detect
biotyp
frequent
although
studi
question
aureu
primari
viral
infect
may
preced
colon
byhinjlua
hinfluenza
may
infect
upper
respiratori
tract
lower
tract
h
buenza
enflotoxin
may
caus
tissu
injuri
inflammatori
reaction
predispos
pseudomona
colon
p
acavginosa
previous
undiagnos
patient
lead
physician
suspect
diagnosi
cf
colon
aureu
h
iue
aae
predispos
colon
rnucoid
strain
ofp
aeruginosa
found
natur
patient
pulmonari
diseasesi
eighti
percent
cf
patient
older
age
year
colon
chronic
mucoid
p
aeruginosa
mucoid
phenotyp
paeruginosa
due
exopolysacchmid
algin
algin
protect
organ
host
defens
prevent
antibodi
coat
phagocosi
algin
also
may
maintain
coloni
format
airway
may
et
character
regulatori
mechan
govern
algin
biosynthesi
identifi
factor
cf
lung
may
particip
transit
nonmucoid
mucoidpaeruginosa
factor
also
contribut
virul
ofp
aeruginosa
p
aeruginosa
adher
respiratori
epithelium
mucln
respiratori
tract
p
aeruginosa
produc
exoproduct
proteas
produc
inflammatori
respons
caus
destruct
ahvay
declin
pulmonari
function
mani
strain
nontyp
secondari
defici
lipopolysaccfiarid
lp
sidechain
although
pathogen
signific
find
clear
cystic
fibrosi
patient
aeruginosa
elev
level
antibodi
direct
aerugino
antigen
howev
antibodi
protect
pulmonari
infectionj
meconium
ileu
import
predictor
earlycolon
p
aeruginosa
sl
howev
correl
genowp
cf
aeruginosa
colon
earli
acquisit
may
due
sever
diseas
earlier
hospit
stay
earli
antibiot
use
crossnifectionfl
antibiot
therapi
elimin
mucoid
strain
winni
cowan
correl
increas
antip
aeruginosa
titer
decreas
pulmonaryfunct
test
impair
mucoclliari
clearanc
due
chronic
inflamm
ailvay
obstruct
contribut
inabl
clear
p
aeruginosa
howev
dissemin
p
aeruginosa
infect
rare
sever
approach
prevent
chronic
p
aeruginosa
colon
investig
cofiort
noninfect
patient
use
attempt
prevent
primari
infect
immuh
lipopolysaccharid
vaccin
whole
ceil
vaccin
agahist
aeruginosa
shown
limit
success
recent
investig
focus
character
potenti
role
defin
polysaccfiarid
vaccin
includ
conjug
vaccin
group
certain
vaccin
induc
antibodi
safe
howev
efficaci
vaccin
still
investig
preval
chronic
p
aeruginosa
colon
reduc
use
cours
oral
ciprofloxacin
inhal
colistin
given
cf
patient
time
first
posit
sputum
cultur
p
aeruginosa
durat
studi
short
month
studi
need
approach
cart
recommend
part
routin
cf
care
speciesspecif
polymeras
chain
reaction
pcr
ribotyp
propos
overcom
limit
cultur
method
p
aeruginosa
attempt
erad
b
cepacia
usual
unsuccess
organ
contain
induc
mactamas
vitro
suscept
test
necessarili
reflect
vivo
respons
gramneg
bacillu
xantlomona
maltophilia
classifi
initi
jo
maltophilia
howev
detali
taxonom
analysi
result
reclassif
organ
associ
mening
pneumonia
mastoid
endocard
urinari
tract
infect
xanthomonca
isol
increasingli
compromis
host
organ
describ
increas
fiequenc
mechan
ventil
patient
intens
care
unit
patient
previou
antimicrobi
therapi
sever
studi
shown
x
maltophi
ia
isol
increasingli
cf
patient
increas
detect
may
due
part
improv
select
media
bacteria
isol
sputum
cf
patient
howev
less
frequent
caus
diseas
previous
discuss
organ
enterobacteriacea
isol
sputum
cf
patient
includ
escherichia
coli
klebsiella
proteu
etrobacl
citrobact
h
parainfluenza
well
streptococcu
pneumonia
also
isol
previous
legionella
pneumophilia
consid
caus
exacerb
cf
patient
base
increas
serum
antibodi
titersi
howev
later
shown
l
pneumophilia
antibodi
crossreact
pseudonwna
antibodi
therefor
actual
incid
legio
ella
cf
remain
character
incid
mycobacteria
tuberculosi
increas
cf
although
candida
altncan
isol
cf
patient
usual
requir
therapi
rmeli
consid
patholog
isol
usual
relat
antibiot
steroid
use
aspergillusfumigatu
anoth
fungn
isol
fiom
cf
patient
invas
aspergillu
mycetoma
uncommon
cf
amphotericin
treatment
usual
need
howev
nc
denc
ergic
bronchopulmonarv
aspergillosi
abpa
among
cf
patient
exacerb
associ
virus
generallywer
indistinguish
viru
isol
howev
exacerb
associ
influenza
viru
gener
sever
associ
vilqls
exacerh
virus
isol
likewis
infect
respiratori
synciti
viru
rsv
shown
caus
frequent
earlyhospit
respiratori
distress
associ
increas
morbid
prolong
hospit
mechan
ventil
result
increas
frequenc
chronic
respiratori
symptom
wors
chest
radiograph
score
although
vaccni
rsv
current
avail
commonli
use
vaccin
includ
inactiv
egggrown
influenza
vaccin
live
attenu
measl
vaccin
influenza
vaccin
given
yemiy
spfitviron
vaccin
patient
younger
age
year
whole
viru
patient
older
age
year
efficacyi
approxim
measl
vaccin
given
singl
initi
dose
month
provid
durabl
immun
patient
second
dose
recommend
stimul
immun
among
vaccin
failur
cf
pulmonari
exacerb
acut
subacut
chang
pulmonari
symptom
relat
increas
airway
secret
exacerb
usual
character
sever
follow
find
increas
product
cough
chang
volum
charact
sputum
dyspnea
reduc
exercis
abil
decreas
activ
lack
energi
increas
respiratori
rate
new
chest
auscult
find
new
infiltr
chest
radiograph
deterior
pulmonari
function
test
oxygen
satur
decreas
appetit
weight
loss
although
univers
accept
definit
exacerb
cf
clinician
would
begin
antibiot
therapi
aggress
chest
physiotherapi
nutrit
support
select
patient
bronchodil
five
find
present
clinician
select
appropri
antimicrobi
therapi
signific
lower
respiratori
tract
organ
must
identifi
sensit
pattern
determin
young
cf
patient
adequ
lower
tract
sampl
difficult
clinician
reli
throat
swab
detect
pathogen
throat
swab
perform
place
swab
phaltrx
collect
secret
cough
may
occur
resuh
lung
secret
cough
onto
swab
therefor
throat
swab
may
contain
oropharyng
flora
cough
occur
lower
airway
specimen
may
collect
ramsey
et
evalu
predict
valu
orophalg
cultur
identifi
lower
airway
bacteri
colon
simultan
perform
oropharyng
cultur
bronchoseopi
posit
predict
valu
posit
oropharyng
cultur
patient
could
cough
expector
sputum
p
aeruginosa
aureu
unfortun
sensitmti
upper
airway
cuhur
forpaeruginosa
auru
therefor
oropharyng
cultur
ield
p
aeruginosa
aureu
higiali
predict
lower
allvcay
colon
neg
cultur
rule
presenc
organ
patient
cf
expector
sputum
sputum
sampl
contain
bacteri
speci
simultan
collect
bronchial
secret
p
aeruginosa
frequent
colon
cf
lung
special
media
use
preven
rapid
growth
obscur
signific
copathogen
recoveri
or
aureu
use
mannitolsalt
agar
recommend
pc
agar
contain
antibiot
suppress
p
aeruginosa
use
routin
isol
fastidi
typic
multiresist
b
cepacia
decontamin
sputum
use
sodium
hydroxid
oxal
acid
recommend
obtain
cultur
mycobacteria
pathogen
may
uncuhur
use
teclmiqu
exampl
role
anaerob
bacteria
virus
fungal
agent
fastidi
bacteria
cf
lung
diseas
character
poorli
detect
difficulti
associ
cultur
develop
pcrbase
detect
method
may
enabl
epidemiolog
studi
potenti
difficult
cultur
pathogen
current
cf
sputum
throat
sampl
cultur
routin
media
blood
agar
plate
chocol
agar
macconkey
agar
mannitolsmt
agar
pc
agar
antinffcrobi
therapi
usual
guid
identif
sensit
pattern
isol
bacteri
pathogen
exacerb
associ
p
aeruginosa
usual
treat
twodrug
regimen
consist
aminogiyzosid
either
thirdgener
cephalosporin
semisyntbet
penicillin
addit
therapi
may
ad
coverag
h
bfiuenza
aureu
need
muhiresist
p
aeruginosa
special
problem
often
combin
antibiot
may
synergist
clinic
effect
despit
pathogen
resistmat
one
individu
gener
pharmacokinet
cf
patient
indic
larger
volum
distribut
increas
total
bodi
clearanc
aminoglycosid
qactam
therefor
recommend
dosag
antimicrobi
cf
patient
reflect
differ
tabl
antibiot
usual
given
week
although
trim
support
tiff
approach
lack
longer
cours
week
may
need
sicker
patient
fluoroquinolon
ciprofloxacin
ofloxacin
come
import
agent
treatment
ofbronchopulmonari
infect
cf
patient
sever
reason
broadspectrum
antibacteri
actmti
includ
p
aeruginosa
aureu
buenza
given
oral
bioaval
remark
properti
diffus
pulmonari
tissu
hroncbial
secret
pharmacokinet
flouroquinolon
similar
cf
noncf
patient
therefor
dose
similar
advers
reaction
occur
patient
revers
drug
discontinu
common
advers
reaction
gastrointestin
skin
reaction
photosensit
mad
minor
central
nervou
system
disord
unfortun
monotherapi
agent
commonli
associ
develop
drug
resist
byp
aeruginosa
tradit
therapi
exacerb
includ
antibiot
physician
therapi
nutrit
support
specif
therapi
organ
failur
sever
newli
accept
investig
approach
may
significantli
improv
prognosi
cf
recombin
human
dnase
rh
dne
develop
recent
use
cf
patient
sputum
cf
patient
contain
larg
amount
extracelhilar
dna
degener
polymorphonucleax
neutrophil
ad
viscosityp
bovin
dnase
shown
reduc
viscos
respiratori
secret
degrad
dna
use
associ
sever
reaction
therapeut
administr
rh
dnase
made
possibl
clone
human
pancreat
dnase
human
pancreat
cdna
librari
human
recombin
dnase
fewer
side
effect
earli
phase
phase
ii
trial
demonstr
improv
pulmonari
function
test
given
aerosolizatinn
cf
patient
phase
iii
paralleldesign
placebocontrol
doubleblind
studi
rh
dnase
therapyin
adult
children
cf
demonstr
safeti
effmaey
administr
rh
dnase
dose
mg
daili
mg
twice
daili
improv
mean
forc
expiratori
volum
second
fevi
reduc
ageadjust
risk
respiratori
exacerb
byapproxim
recent
aerosol
antibiot
use
provid
direct
deliveri
aminoglycosid
lower
alrway
cf
patient
inhal
aerosol
antibiot
high
concentr
antiblotlc
reach
site
infect
decreas
risk
system
effect
midim
absorpt
tm
ramsey
et
recent
compar
aerosol
tobramycin
placebo
demonstr
improv
forc
vital
capac
fvc
fevi
forc
expiratori
flow
middl
half
forc
vital
capac
well
decreas
densiti
ofl
aeruginosa
sputum
aerosol
administr
safe
indic
lack
detect
ototox
chronic
infect
cf
result
chronic
inflamm
associ
lung
destruct
antlinflammatori
agent
studi
cf
popul
limit
host
respons
ahernatemay
therapi
preddison
test
sever
clinic
trial
auerbach
et
alm
report
encourag
result
improv
respiratori
statu
increas
patient
weight
howev
subsequ
studi
rosenstein
eigan
report
prednison
mgkg
altern
day
associ
cataract
growth
retard
glucos
abnorm
ibuprofen
current
investig
antiinflammatori
agent
inhibit
neutrophil
function
fewer
side
effect
corticosteroid
placebocontrol
doublebhnd
studi
demonstr
ibuproien
caw
safe
dose
children
pouprofen
administ
consist
four
year
slow
growth
lung
diseas
without
seriou
advers
effect
popul
cf
patient
age
year
note
activ
immun
cf
children
unsuccess
attempt
prevent
acquisit
pseudomona
antipseudornona
therapi
ath
passiv
immun
also
examin
infus
intraven
immunoglobdiin
mg
cf
patient
recent
test
efficaci
reduc
pseudomo
infect
acut
exacerb
doubleblind
studi
transient
improv
expiratori
flow
measur
treat
group
detect
howev
length
hospit
stay
shortenedl
investig
passiv
activ
immun
need
amiiorid
sodimn
transport
blocker
amelior
basic
cf
airway
defect
epitheli
ion
transport
preliminari
studi
shown
improv
mucociliari
clearanc
pulmonari
function
test
sever
group
activ
investig
somat
gene
therapi
cf
current
strategyi
deliv
normal
gene
epithelium
cf
airway
sever
viral
vector
investig
util
dissemin
gene
airway
preliminari
studi
underway
determin
safe
efficacyof
therapi
gene
therapi
may
provid
signific
advanc
redudng
need
antibiot
treat
infect
cf
local
correct
genet
defect
antibiot
may
import
extend
surviv
cf
patient
howev
widespread
use
antibiot
associ
emerg
mtibloticresist
bacteria
seudomona
emerg
import
pathogen
cf
resist
extens
studi
p
aeraginosa
resist
antibiot
aminoglycosid
quinolon
emerg
sometim
difficult
determin
signific
antibiot
resist
total
erad
antibioticsensit
bacteri
speci
cf
patient
treat
antibiot
rare
achiev
howev
patient
experi
improv
clinic
symptom
pulmonari
function
despit
reduct
sputum
concentr
sensit
speci
mortal
cf
frequent
secondari
respiratorydecompens
infect
multiresist
organ
may
contribut
unfortun
scenario
mode
transmiss
infect
cf
appear
vari
lipuma
et
demonstr
persontoperson
transmiss
b
cepado
studi
implic
acquisit
cf
summer
camp
occasion
contamin
equip
also
ba
occur
ni
govan
et
al
examin
transmiss
within
cf
social
group
also
detail
b
cepada
contamin
environment
surfac
within
clinic
anoth
studi
examin
transmiss
ofp
aeruginosa
among
cf
patient
found
high
rate
acquisit
among
cf
sibl
patient
attend
cf
camp
clinic
base
similar
studi
cohor
ting
cf
patient
muhiresist
organ
recommend
definit
therapi
cf
includ
lung
transplant
despit
antibiot
therapi
cf
patient
develop
sever
pulmonari
impair
lung
transplant
becom
consider
indic
cf
lung
transplant
similar
diseas
patient
usual
sever
hypoxemia
oxygen
depend
reduc
exercis
toler
mean
fev
less
respiratori
failur
accompani
repeat
pulmonari
infect
continu
weight
loss
despit
nutrit
support
psycholog
instabl
irrevers
organ
lung
transplant
cf
patient
develop
opportunist
infect
similar
noncf
patient
initi
report
show
increas
incid
paeudomona
pneumonia
howev
recent
report
show
p
aeruginosa
predomin
pathogenb
cepacia
import
sourc
morbid
mortal
especi
patient
colon
b
cepacia
certain
group
begun
aggress
program
limit
organ
transplant
cohort
antibiot
prophylaxi
aggress
antibiot
therapi
infect
sinu
drainag
surgeri
h
longterm
efficaci
lung
transplant
patient
cf
yet
known
